# OnCo record dt2216 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/dt2216/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "dt2216" ;
  schema:name "DT2216"@en ;
  schema:alternateName "DT-2216"@en, "BCL-XL PROTAC DT2216"@en ;
  schema:description "DT2216 is an experimental drug from Dialectic Therapeutics that makes cancer cells destroy BCL-XL, a protein they use to avoid dying. It was designed to avoid the sharp fall in platelets that stopped earlier drugs against the same protein."@en ;
  schema:url <https://onco.cc/drugs/dt2216/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.dialectictherapeutics.com/>, <https://doi.org/10.1038/s41591-019-0668-z>, <https://doi.org/10.1186/s13045-025-01753-8>, <https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C179922>, <https://clinicaltrials.gov/study/NCT04886622>, <https://clinicaltrials.gov/study/NCT06620302>, <https://clinicaltrials.gov/study/NCT06964009> ;
  onco:status "phase-2" ;
  onco:modality "small molecule (PROTAC degrader)" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/bcl2-inhibitors/> .